原发性肝癌肝外动脉供血的dsa表现及临床分析-dsa manifestations and clinical analysis of extrahepatic arterial blood supply in primary liver cancer.docxVIP

PAGE PAGE 10 The DSA performance and clinical research of extrahepatic artery in Primary liver cancer Abstract:objective:Researching the DSA Performance of extrahepatic artery in primary liver, discussing the relevant factors,the redisposing factors, and the basic rule of extrahepatic arterial blood supply in primary liver cancer, Expecting to improve the effect of interventional treatment further. Methods: Selecting the DSA data of 356 patients with primary liver cancer that line to TACE treatment to analysis retrospectively. All patients make enhanced CT scan and determine the diameter of tumor before the first TACE treatment, the tumor were also classified as surface or non-surface according to anatomical location. Selecting carboplatin 0.2g and mitomycin 10mg for infusion chemotherapy, the embolic agent select doxorubicin 10 mg iodized oil emulsifier 5-20ml. The DSA data was observed by three experienced interventional radiologist above physician, Analysising whether existsing extrahepatic artery or not about the liver tumor, If the extrahepatic artery exist,dividing them into the variability of blood supply and the extrahepatic collateral blood, then make the two categories classified separately. For variability donors, describe their origin, distribution and constituent ratio. At the same time, contrasting our research with Li Jiakai and Michels; For extrahepatic collateral blood donors, what is more, make correlation analysis and statistical inference between extrahepatic collateral and tumor location, tumor size, hepatic artery occlusion and TACE times. Results: 1. Among the 356 patients: typeⅠ295 cases, type Ⅱ 15 cases, type Ⅲ 32 cases , type Ⅳ 0 cases, type Ⅴ 8 cases , type Ⅵ 0 cases, othet AbHA 6 cases. 61 cases were found existing variant hepatic artery, The total number of variant hepatic artery are 73, Among them: AbRHA 41 (56.16%), AbMHA 3 (4.11%), AbLHA 18 (24.66%), AbPHA 6 (8.22%), AbCHA5(6.85%); 2. There is no significant difference between our